Radiotherapy Planning Using Fluciclovine PET in Patients With Newly Diagnosed Glioblastoma

PHASE2UnknownINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

June 7, 2021

Primary Completion Date

March 30, 2024

Study Completion Date

March 30, 2024

Conditions
Newly Diagnosed Glioblastoma
Interventions
DRUG

Fluciclovine PET guided Radiotherapy

PET+MRI Based There is no GTV\_5400. The GTV\_6000 will be defined as the surgical cavity inclusive of any remaining tumor enhancement and the hypermetabolic volume. CTV\_5400 will include the GTV\_6000 plus a margin of 1.0 cm which may be reduced around natural barriers to tumor growth such as the skull, ventricles, falx, etc. CTV\_5400 must also include the entirety of the GTV\_6000. There is no CTV\_6000. PTV\_5400 is the CTV\_5400 plus a geometric 3 mm expansion in all dimensions; PTV\_6000 is GTV\_6000 plus a geometric 3 mm expansion in all dimensions. PTV may extend beyond bony margins and the skin surface. The PTV\_5400 must contain the PTV\_6000. In the setting of multi-focal disease, the primary target volumes will be defined as above, but for satellite lesions, the GTV\_6000 will be defined as any tumor enhancement and hypermetabolic volume. There will be no CTV\_6000. PTV\_6000 will be defined as GTV\_6000 plus a geometric 3 mm expansion in all dimensions.

Trial Locations (1)

85013

RECRUITING

St. Joseph's Hospital and Medical Center, Phoenix

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Barrow Neurological Foundation

OTHER

collaborator

Arizona Biomedical Research Commission (ABRC)

OTHER

collaborator

Blue Earth Diagnostics

INDUSTRY

lead

St. Joseph's Hospital and Medical Center, Phoenix

OTHER

NCT04840069 - Radiotherapy Planning Using Fluciclovine PET in Patients With Newly Diagnosed Glioblastoma | Biotech Hunter | Biotech Hunter